Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

Similar articles for PubMed (Select 24107399)


Pleiotropic effects of peroxisome proliferator-activated receptor γ and δ in vascular diseases.

Cheang WS, Fang X, Tian XY.

Circ J. 2013;77(11):2664-71. Epub 2013 Oct 10. Review.


Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.

Toyama K, Nakamura T, Kataoka K, Yasuda O, Fukuda M, Tokutomi Y, Dong YF, Ogawa H, Kim-Mitsuyama S.

Biochem Biophys Res Commun. 2011 Jul 8;410(3):508-13. doi: 10.1016/j.bbrc.2011.06.012. Epub 2011 Jun 7.


Protective role of vascular smooth muscle cell PPARγ in angiotensin II-induced vascular disease.

Marchesi C, Rehman A, Rautureau Y, Kasal DA, Briet M, Leibowitz A, Simeone SM, Ebrahimian T, Neves MF, Offermanns S, Gonzalez FJ, Paradis P, Schiffrin EL.

Cardiovasc Res. 2013 Mar 1;97(3):562-70. doi: 10.1093/cvr/cvs362. Epub 2012 Dec 17.


Dominant negative PPARγ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle.

Pelham CJ, Keen HL, Lentz SR, Sigmund CD.

Am J Physiol Regul Integr Comp Physiol. 2013 May 1;304(9):R690-701. doi: 10.1152/ajpregu.00607.2012. Epub 2013 Feb 27.


Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.

Duan SZ, Usher MG, Mortensen RM.

Circ Res. 2008 Feb 15;102(3):283-94. doi: 10.1161/CIRCRESAHA.107.164384. Review.


Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.

Touyz RM, Schiffrin EL.

Vascul Pharmacol. 2006 Jul;45(1):19-28. Epub 2006 Jun 16. Review.


Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.

Marx N, Duez H, Fruchart JC, Staels B.

Circ Res. 2004 May 14;94(9):1168-78. Review.


Effects of PPARγ on hypertension, atherosclerosis, and chronic kidney disease.

Sugawara A, Uruno A, Kudo M, Matsuda K, Yang CW, Ito S.

Endocr J. 2010;57(10):847-52. Epub 2010 Sep 28. Review.


Peroxisome proliferator-activated receptor gamma and cardiovascular diseases.

Takano H, Komuro I.

Circ J. 2009 Feb;73(2):214-20. Epub 2009 Jan 8. Review.


Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production.

Kleinhenz JM, Kleinhenz DJ, You S, Ritzenthaler JD, Hansen JM, Archer DR, Sutliff RL, Hart CM.

Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1647-54. doi: 10.1152/ajpheart.00148.2009. Epub 2009 Aug 7.


Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension.

Chang L, Villacorta L, Zhang J, Garcia-Barrio MT, Yang K, Hamblin M, Whitesall SE, D'Alecy LG, Chen YE.

Circulation. 2009 Apr 28;119(16):2161-9. doi: 10.1161/CIRCULATIONAHA.108.815803. Epub 2009 Apr 13.


Pleiotropic vascular effects of PPARgamma ligands.

Collins AR.

Drug News Perspect. 2003 May;16(4):197-204. Review.


Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma.

Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK.

J Clin Invest. 2004 Dec;114(11):1564-76.


Synergistic effect of peroxisome proliferator activated receptor-gamma and liver X receptor-alpha in the regulation of inflammation in macrophages.

Piraino G, Cook JA, O'Connor M, Hake PW, Burroughs TJ, Teti D, Zingarelli B.

Shock. 2006 Aug;26(2):146-53.


Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice.

Ishii N, Matsumura T, Kinoshita H, Fukuda K, Motoshima H, Senokuchi T, Nakao S, Tsutsumi A, Kim-Mitsuyama S, Kawada T, Takeya M, Miyamura N, Nishikawa T, Araki E.

Arterioscler Thromb Vasc Biol. 2010 Aug;30(8):1598-605. doi: 10.1161/ATVBAHA.109.202309. Epub 2010 May 27.


Effects of PPARγ agonists against vascular and renal dysfunction.

Sugawara A, Uruno A, Matsuda K, Saito-Ito T, Funato T, Saito-Hakoda A, Kudo M, Ito S.

Curr Mol Pharmacol. 2012 Jun;5(2):248-54. Review.


High-mobility group A1 protein: a new coregulator of peroxisome proliferator-activated receptor-γ-mediated transrepression in the vasculature.

Bloch M, Prock A, Paonessa F, Benz V, Bähr IN, Herbst L, Witt H, Kappert K, Spranger J, Stawowy P, Unger T, Fusco A, Sedding D, Brunetti A, Foryst-Ludwig A, Kintscher U.

Circ Res. 2012 Feb 3;110(3):394-405. doi: 10.1161/CIRCRESAHA.111.253658. Epub 2011 Dec 29.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk